Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Beheer

Beheer criteriumcontroles 2/4

De CEO Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd is Da Jun Zhao, benoemd in May2023, heeft een ambtstermijn van 1.5 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 1.88M, bestaande uit 89.9% salaris en 10.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.51% van de aandelen van het bedrijf, ter waarde HK$ 111.30M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 1.5 jaar.

Belangrijke informatie

Da Jun Zhao

Algemeen directeur

CN¥1.9m

Totale compensatie

Percentage CEO-salaris	89.9%
Dienstverband CEO	1.5yrs
Eigendom CEO	1.5%
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	1.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Da Jun Zhao's beloning veranderd ten opzichte van Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	CN¥105m
Jun 30 2024	n/a	n/a	CN¥111m
Mar 31 2024	n/a	n/a	CN¥102m
Dec 31 2023	CN¥2m	CN¥2m	CN¥109m
Sep 30 2023	n/a	n/a	CN¥191m
Jun 30 2023	n/a	n/a	CN¥242m
Mar 31 2023	n/a	n/a	CN¥142m
Dec 31 2022	CN¥3m	CN¥2m	CN¥138m
Sep 30 2022	n/a	n/a	CN¥132m
Jun 30 2022	n/a	n/a	CN¥112m
Mar 31 2022	n/a	n/a	CN¥213m
Dec 31 2021	CN¥5m	CN¥2m	CN¥213m
Sep 30 2021	n/a	n/a	CN¥198m
Jun 30 2021	n/a	n/a	CN¥201m
Mar 31 2021	n/a	n/a	CN¥188m
Dec 31 2020	CN¥3m	CN¥1m	CN¥165m
Sep 30 2020	n/a	n/a	CN¥191m
Jun 30 2020	n/a	n/a	CN¥165m
Mar 31 2020	n/a	n/a	CN¥204m
Dec 31 2019	CN¥3m	CN¥1m	CN¥227m
Sep 30 2019	n/a	n/a	CN¥151m
Jun 30 2019	n/a	n/a	CN¥151m
Mar 31 2019	n/a	n/a	CN¥91m
Dec 31 2018	CN¥2m	CN¥1m	CN¥112m
Sep 30 2018	n/a	n/a	CN¥95m
Jun 30 2018	n/a	n/a	CN¥78m
Mar 31 2018	n/a	n/a	CN¥77m
Dec 31 2017	CN¥1m	CN¥1m	CN¥75m

Compensatie versus markt: De totale vergoeding ($USD 260.10K ) Da Jun } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 478.62K ).

Compensatie versus inkomsten: De vergoeding van Da Jun is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Da Jun Zhao (54 yo)

1.5yrs

Tenure

CN¥1,882,870

Compensatie

Mr. Da Jun Zhao has been an Executive Director at Taizhou SPH Pharmaceutical Co., Ltd. since January 2002. Mr. Zhao Co-Founded Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.in November 1996 and ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Da Jun Zhao	Co-Founder	1.5yrs	CN¥1.88m	1.51% HK$ 111.3m
Xue Yan	CFO, Deputy GM	14.3yrs	CN¥1.18m	0.20% HK$ 14.5m
Jun Li	Co-Founder & Deputy GM	28yrs	CN¥2.22m	0.87% HK$ 64.3m
Luo Chun Wang	Core Technical Personnel	no data	geen gegevens	0.11% HK$ 8.3m
Dai Qing Yu	Deputy General Manager	1.5yrs	geen gegevens	0.064% HK$ 4.7m
Yu Chen	Deputy General Manager	1.5yrs	geen gegevens	0.018% HK$ 1.3m
Xiaowen Li	Deputy General Manager	1.5yrs	geen gegevens	0.020% HK$ 1.5m

1.5yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1349 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Da Jun Zhao	Co-Founder	22.8yrs	CN¥1.88m	1.51% HK$ 111.3m
Xue Yan	CFO, Deputy GM	1.5yrs	CN¥1.18m	0.20% HK$ 14.5m
Xiao Yang Yu	Non-Executive Director	11.5yrs	geen gegevens	geen gegevens
Ai Guo Zhou	Supervisor	1.5yrs	geen gegevens	geen gegevens
Bo Shen	Non Executive Director	12.4yrs	geen gegevens	geen gegevens
Jian Huang	Independent Chairman of Supervisory Board	7.4yrs	geen gegevens	geen gegevens
Hong Guang Wang	Independent Non-Executive Director	1.5yrs	CN¥116.67k	geen gegevens
Siu Wing Lam	Independent Non-Executive Director	1.5yrs	geen gegevens	geen gegevens
Pei Long Xu	Independent Non-Executive Director	1.5yrs	CN¥116.67k	geen gegevens
Ya Nan Qu	Employee Representative Supervisor	1.5yrs	geen gegevens	0.0038% HK$ 277.7k

1.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1349 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw bestuur.

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.014 (vs CN¥0.021 in 3Q 2023)

Investor sentiment deteriorates as stock falls 36%

Now 57% overvalued after recent price rise

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 21%

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient Enrolled in Phase II Clinical Trial in the United States of Hemoporfin for Injection for the Treatment of Port Wine Birthmark

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient Enrolled in Phase III Clinical Trial of FDA018 Antibody Drug Conjugate for Injection for the Treatment of Triple Negative Breast Cancer

Upcoming dividend of HK$0.022 per share

Second quarter 2024 earnings released

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. announces Annual dividend, payable on October 10, 2024

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient in Phase I Clinical Trial of Fz-Ad005 Antibody Drug Conjugate for Injection

Upcoming dividend of CN¥0.07 per share

First quarter 2024 earnings released

Now 21% overvalued

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Aug 15, 2024

Full year 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.13 in FY 2022)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug

Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.11 in 3Q 2022)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC

New major risk - Earnings quality

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors

Less than half of directors are independent

Upcoming dividend of CN¥0.07 per share at 2.7% yield

First quarter 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.005 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.20 in FY 2021)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice for the Investigational New Drug Application

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces Indicative Announcement-First Patient Enrolled in Phase I Clinical Trial of FDA022 Antibody Drug Conjugate for Injection for the Treatment of Advanced Solid Tumors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issue by the National Medical Products Administration of the PRC

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.046 in 3Q 2021)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q3, 2022 Results on Oct 27, 2022

Second quarter 2022 earnings released

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces Supplemental Announcement Related to Earnings Guidance for the Six Months Ended 30 June 2022

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Received the Acceptance Notice of the Quality and Efficacy Consistency Evaluation of Generic Drugs for Chemical Injection

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Approves Final Dividend for the Year Ended 31 December 2021, Payable on or Before 26 August 2022

Upcoming dividend of CN¥0.07 per share

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives the Acceptance Notice Issued by the National Medical Products Administration of the Prc

First quarter 2022 earnings released

Less than half of directors are independent

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q1, 2022 Results on Apr 29, 2022

Full year 2021 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in FY 2020)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 26 August 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.058 (vs CN¥0.045 in 2Q 2020)

First quarter 2021 earnings released

Full year 2020 earnings released

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd